ArticleEuropean journal of nuclear medicine and molecular imaging2026
Spatiotemporal dynamics of tau pathology and neurodegeneration in Medial Temporal Lobe (MTL) subregions across alzheimer's disease progression: A multimodal imaging study using second-generation tracer [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo characterize the spatiotemporal progression of tau pathology and neurodegeneration across medial temporal lobe (MTL) subregions—critical hubs for memory and early Braak-stage pathology—in Alzheimer’s disease (AD), using tau-PET with the second-generation tracer and MRI.
methods114 participants underwent [18F]florbetapir, [18F]MK-6240 PET and structural MRI, then classified into four groups (32 AD Aβ+, 20 MCI Aβ+, 21 CU Aβ+, 41 CU Aβ−). Tau uptake and brain volumetry were measured in MTL subregions: anterior hippocampus (aHIP), Brodmann areas 35/36 (BA35/36), entorhinal cortex (ERC), parahippocampal cortex (PHC), and posterior hippocampus (pHIP), then compared among groups. Correlations between tau deposition and volumetry, also with cognitive scores (MMSE, AVLT, BNT) were analyzed.
resultsTau deposition and brain atrophy followed an anteroposterior gradient throughout MTL subregions. Tau pathology initially emerged in anterior MTL regions (ERC, BA35, and aHIP) during preclinical stages (CU Aβ+), then progressively spread to posterior MTL subregions (PHC and pHIP) as cognitive decline advances to MCI and AD. Correlations between tau deposition and neurodegeneration progressively strengthened with disease progression, peaking in AD Aβ + group (p < 0.001). Elevated tau deposition across MTL subregions inversely correlated with cognitive performance, with reduced volumes in specific subregions conferring additional predictive value.
conclusionTau pathology progresses from anterior to posterior MTL subregions, co-occurring with neurodegeneration and memory deficits. These spatiotemporal patterns captured by [18F]MK-6240 PET may provide detailed understanding of AD continuum, especially help to guide early therapies.
Indexed as
Identifiers
41483305What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.